Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy".
- Hoerner-Rieber J Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
- Duma M Department of Radiation Oncology, Technical University Munich, Germany.
- Blanck O Department of Radiation Oncology, UKSH Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
- Hildebrandt G Department of Radiation Oncology, University of Rostock, Rostock, Germany.
- Wittig A Department of Radiotherapy and Radiation Oncology, Philipps-University Marburg, University Hospital Giessen and Marburg, Germany.
- Lohaus F Department of Radiation Oncology, Medical Faculty and University Hospital C.G. Carus, Technical University Dresden, Germany.
- Flentje M Department of Radiation Oncology, University Hospital Wuerzburg, Germany.
- Mantel F Department of Radiation Oncology, University Hospital Wuerzburg, Germany.
- Krempien R Department of Radiation Oncology, Helios Klinikum Berlin Buch, Berlin, Germany.
- Eble MJ Department of Radiation Oncology, University Hospital Aachen, Aachen, Germany.
- Kahl KH Department of Radiation Oncology, Hospital Augsburg, Germany.
- Boda-Heggemann J Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Germany.
- Rieken S Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
- Guckenberger M Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.
- 2017-12-23
Published in:
- Journal of thoracic disease. - 2017
Renal cell carcinoma (RCC)
extracranial stereotactic radiotherapy
lung metastases
radioresistance
stereotactic body radiotherapy (SBRT)
English
Background
Renal cell carcinoma (RCC) is traditionally considered to be radioresistant. Radiotherapy response rates are believed to improve with hypofractionated, high dose stereotactic body radiotherapy (SBRT). However, limited data exist regarding the role of SBRT in the treatment of pulmonary metastases.
Methods
The working group "Stereotactic Radiotherapy" of the German Society of Radiation Oncology analyzed its multi-institutional database of more than 700 patients who received SBRT for pulmonary metastases. Treatment was performed at 10 centers between 2001 and 2016. Patients with metastatic RCC were included in the study. Tumor characteristics, treatment details, and follow-up data including survival, local control (LC), distant metastases, and toxicity were evaluated.
Results
A total of 46 RCC patients treated with SBRT for 67 lung metastases were identified, who received a median total biologically effective dose (BEDiso) at planning target volume (PTV) isocenter of 117.0 Gy (range, 48.0-189.0 Gy). A median fractional dose of 20.8 Gy at isocenter (range, 6.0-37.9 Gy) was administered in a median number of 3 fractions (1-8 fractions). After a median follow-up time of 28.3 months for all patients, 1- and 3-year LC rates were 98.1% and 91.9%, with corresponding 1- and 3-year overall survival (OS) of 84.3% and 43.8%, respectively. Pulmonary metastases treated with BEDiso ≥130 Gy showed a trend for superior LC (P=0.054). OS was significantly improved in both uni- and multivariate analysis for patients with higher Karnofsky performance scale, lower maximum pulmonary metastasis diameter and lack of post-SBRT systemic therapy due to progression (P=0.014; P=0.049; P=0.006). Only mild acute and late toxicity was reported.
Conclusions
SBRT for pulmonary metastases from RCC was associated with low treatment-associated toxicity, promising survival, and excellent LC, especially in those patients receiving a BEDiso ≥130 Gy.
Renal cell carcinoma (RCC) is traditionally considered to be radioresistant. Radiotherapy response rates are believed to improve with hypofractionated, high dose stereotactic body radiotherapy (SBRT). However, limited data exist regarding the role of SBRT in the treatment of pulmonary metastases.
Methods
The working group "Stereotactic Radiotherapy" of the German Society of Radiation Oncology analyzed its multi-institutional database of more than 700 patients who received SBRT for pulmonary metastases. Treatment was performed at 10 centers between 2001 and 2016. Patients with metastatic RCC were included in the study. Tumor characteristics, treatment details, and follow-up data including survival, local control (LC), distant metastases, and toxicity were evaluated.
Results
A total of 46 RCC patients treated with SBRT for 67 lung metastases were identified, who received a median total biologically effective dose (BEDiso) at planning target volume (PTV) isocenter of 117.0 Gy (range, 48.0-189.0 Gy). A median fractional dose of 20.8 Gy at isocenter (range, 6.0-37.9 Gy) was administered in a median number of 3 fractions (1-8 fractions). After a median follow-up time of 28.3 months for all patients, 1- and 3-year LC rates were 98.1% and 91.9%, with corresponding 1- and 3-year overall survival (OS) of 84.3% and 43.8%, respectively. Pulmonary metastases treated with BEDiso ≥130 Gy showed a trend for superior LC (P=0.054). OS was significantly improved in both uni- and multivariate analysis for patients with higher Karnofsky performance scale, lower maximum pulmonary metastasis diameter and lack of post-SBRT systemic therapy due to progression (P=0.014; P=0.049; P=0.006). Only mild acute and late toxicity was reported.
Conclusions
SBRT for pulmonary metastases from RCC was associated with low treatment-associated toxicity, promising survival, and excellent LC, especially in those patients receiving a BEDiso ≥130 Gy.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.21037/jtd.2017.10.108
- PMID 29268521
- Persistent URL
- https://sonar.rero.ch/global/documents/200067
Statistics
Document views: 39
File downloads:
- Full-text: 0